Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder affecting approximately 1% of the population, characterized by difficulties with social interaction and communication. Studies have identified more than 200 genes linked to ASD, particularly those involved in chromatin remodeling and synaptic neuronal connectivity (CHD8, SCN2A, NLGN3-4X, SHANK1-3). The goal of the project is to decipher the biological mechanisms underlying ASD in order to develop therapeutic strategies, using innovative preclinical models such as organoids.
A child diagnosed with an autism spectrum disorder in accordance with clinical practice guidelines
A sibling without an autism spectrum disorder (SRS < 65)
Biological parents
Children and parents must be enrolled in a social security program, Universal Health Coverage (CMU), or an equivalent program.
Refusal to undergo a blood test
Uncontrolled (unstabilized) medical condition (including psychiatric conditions) that precludes participation in the study
Sibling with an SRS score > 65 at screening or under 2 years old
A child with an autism spectrum disorder, a sibling over the age of 2 who does not have an autism spectrum disorder, and biological parents
Cohort
Prospective
Not listed
Production of organoïds
To study the cellular mechanisms affected by the presence of the abnormalities identified in the participant with ASD
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
